Monitoring
US guidelines recommend surveillance for local recurrence with 3- to 6-monthly clinical review and physical examination in the first 2 years, then every 6-12 months for a further 3-5 years, and then annually.[100][217][252] Consideration should be given to assessing patients with high-risk disease more frequently (e.g., every 3 months for the first 2 years). Annual cervical/vaginal cytology may be considered for detection of lower genital tract dysplasia.
For patients with high-risk early stage disease who received adjuvant radiation or chemoradiation, and those with locally advanced disease, initial post-treatment fluorodeoxyglucose-positron emission tomography (FDG-PET)/computed tomography (CT) or CT is recommended within 3-6 months to assess response to treatment.[100]
For patients with stage I disease who had fertility-sparing treatment, magnetic resonance imaging (MRI) should be considered at 6 months after surgery, then yearly for 2-3 years.[100]
Additional imaging (e.g., MRI pelvis, site-specific PET/CT) should be considered if recurrence or metastasis is suspected.[100]
Use of this content is subject to our disclaimer